Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 1;137(7):756-765.
doi: 10.1001/jamaophthalmol.2019.0900.

Association of Statin Use and High Serum Cholesterol Levels With Risk of Primary Open-Angle Glaucoma

Affiliations

Association of Statin Use and High Serum Cholesterol Levels With Risk of Primary Open-Angle Glaucoma

Jae H Kang et al. JAMA Ophthalmol. .

Retraction in

Abstract

Importance: The use of statins (hydroxymethylglutaryl coenzyme A inhibitors) has been associated with a lower risk of primary open-angle glaucoma (POAG); however, results have been conflicting, and little is known about the association between high cholesterol levels and POAG.

Objective: To assess the association of elevated cholesterol levels and statin use with incident POAG.

Design, setting, and participants: This study used data collected biennially from participants aged 40 years or older who were free of glaucoma and reported eye examinations, within 3 population-based cohorts: the Nurses' Health Study (N = 50 710; followed up from 2000 to 2014), the Nurses' Health Study 2 (N = 62 992; 1999-2015), and the Health Professionals Follow-up Study (N = 23 080; 2000-2014). Incident cases of POAG were confirmed by medical record review. The analyses were performed in January 2019.

Exposures: Biennially updated self-reported information on elevated cholesterol level status, serum cholesterol levels, and duration of statin use.

Main outcomes and measures: Multivariable-adjusted relative risks (RRs) and 95% CIs were estimated using Cox proportional hazards regression models on pooled data, with stratification by cohort.

Results: Among the 136 782 participants in the 3 cohorts (113 702 women and 23 080 men), 886 incident cases of POAG were identified. Every 20-mg/dL increase in total serum cholesterol was associated with a 7% increase in risk of POAG (RR, 1.07 [95% CI, 1.02-1.11]; P = .004). Any self-reported history of elevated cholesterol was also associated with a higher risk of POAG (RR, 1.17 [95% CI, 1.00-1.37]). A history of any statin use was associated with a 15% lower risk of POAG (RR, 0.85 [95% CI, 0.73-0.99]). Use of statins for 5 or more years vs never use of statins was associated with a 21% lower risk of POAG (RR, 0.79 [95% CI, 0.65-0.97]; P = .02 for linear trend). The association between use of statins for 5 or more years vs never use of statins and risk of POAG was more inverse in those who were older (≥65 years: RR, 0.70 [95% CI, 0.56-0.87] vs <65 years: RR, 1.05 [95% CI, 0.68-1.63]; P = .01 for interaction).

Conclusions and relevance: Among adults aged 40 years or older, higher serum cholesterol levels were associated with higher risk of POAG, while 5 or more years of statin use compared with never use of statins was associated with a lower risk of POAG.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Stein reported receiving grants from the National Institutes of Health and grants from Research to Prevent Blindness during the conduct of the study. Dr Khawaja reported receiving personal fees from Allergan, Novartis, Thea, Grafton Optical, and Santen outside the submitted work. Dr Rosner reported receiving grants from the National Institutes of Health during the conduct of the study. Dr Kang reported receiving grants from the National Institutes of Health during the conduct of the study. Dr Wiggs reported receiving grants from the National Eye Institute during the conduct of the study and grants from the National Eye Institute outside the submitted work. Dr Pasquale reported receiving personal fees from Bausch & Lomb, Eyenovia, and Verily Inc outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. Association Between Total Serum Cholesterol Level and Risk of Primary Open-Angle Glaucoma
A Cox proportional hazards regression cubic spline plot showing the association (with 95% CI bands) between total serum cholesterol and relative risk of primary open-angle glaucoma using 3 knots and increments of 20 mg/dL (to convert to millimoles per liter, multiply by 0.0259). The test for whether a nonlinear association vs a simple linear association is a better fit to the data was not significant (P = .44); therefore, a linear association can be considered a good fit to the data. Every 20-mg/dL increase in total serum cholesterol was associated with a 7% increase in risk of primary open-angle glaucoma (relative risk, 1.07; 95% CI, 1.02-1.11; P = .004).

Comment in

Similar articles

Cited by

References

    1. Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: food sources and bioavailability. Am J Clin Nutr. 2004;79(5):727-747. doi:10.1093/ajcn/79.5.727 - DOI - PubMed
    1. US Preventive Services Task Force Statin use for the primary prevention of cardiovascular disease in adults: recommendation statement. Am Fam Physician. 2017;95(2). - PubMed
    1. Downs JR, Clearfield M, Weis S, et al. . Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615-1622. doi:10.1001/jama.279.20.1615 - DOI - PubMed
    1. Sillesen H, Amarenco P, Hennerici MG, et al. ; Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators . Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2008;39(12):3297-3302. doi:10.1161/STROKEAHA.108.516450 - DOI - PubMed
    1. Osmak M. Statins and cancer: current and future prospects. Cancer Lett. 2012;324(1):1-12. doi:10.1016/j.canlet.2012.04.011 - DOI - PubMed

Publication types

MeSH terms

Substances